Neuropathologically, LATE is defined and staged by virtue of the presence of intracytoplasmic deposits of TDP-43 within specific, reproducible areas of the neuraxis; early stages originate inclusions within medial limbic structures, while advanced stages show inclusions in cerebral neocortex. paraffin-embedded tissues, 2G11 and 2H1 robustly identified the classic inclusions of ALS and FTLD-TDP, and efficaciously provided a diagnosis of LATE in cases of AD and LBD. These novel antibodies label aberrant intracytoplasmic protein inclusions without relying on hyperphosphorylated epitopes, and provide elegant discrimination between TDP-43 and tau neurofibrillary tangles within neurodegenerative comorbidity. Keywords:TDP-43, LATE, FTLD-TDP, ALS, immunohistochemistry, neuropathology == Introduction == The importance of transactive response DNA-binding protein of 43 kilodaltons (TDP-43) in neurodegenerative diseases became clear upon the discovery that aberrant, cytoplasmic inclusions of the protein comprise the pathologic substrate of most cases of sporadic amyotrophic lateral sclerosis (ALS) [1]. Similarly, the protein deposits of frontotemporal lobar degeneration with ubiquitinated inclusions (FTLD-U), whose inclusions were previously characterized only by their non-specific association to ubiquitin, were found to be composed of aberrant cytoplasmic TDP-43, ultimately warranting a taxonomic change to frontotemporal lobar degeneration with TDP-43 proteinopathy (FTLD-TDP) [1]. TDP-43 was initially discovered as a protein capable of binding the transactive response DNA element of the human immunodeficiency computer virus (HIV) [2]. In its physiologic state, the TDP-43 protein primarily localizes to the cell nucleus, reflective of its function related to regulation of RNA transcription, splicing, and translation via RNA and DNA interactions through its RNA recognition motif 1 (RRM1) and RNA recognition motif 2 (RRM2) domains [3,4]. In mouse models, TDP-43 has been shown to be expressed throughout the primitive neuroepithelium during embryonic development, and within cerebral neocortical, hippocampal, cerebellar, and spinal cord structures in adult tissue [5]. TDP-43 exhibits a high degree of conservation between species [6], with approximately 96% of amino acid residue concordance with mouse (Mus musculus) TAK-779 protein (https://www.ncbi.nlm.nih.gov/protein/Q13148.1andhttps://www.ncbi.nlm.nih.gov/protein/NP_663531.1) [6]. As the study of TDP-43s contribution to neurodegeneration continued, it became increasingly acknowledged TAK-779 that TDP-43 inclusions occur outside of the classical distribution associated with ALS and FTLD-TDP. TDP-43 proteinopathy outside of the ALS and FTLD spectrum has been ascribed to evolving terminologies, which have included hippocampal sclerosis of aging and cerebral age-related TDP-43 and sclerosis (CARTS) [7,8]. In a recent attempt to discretely articulate TDP-43 proteinopathy outside of ALS and FTLD, the term Limbic-Predominant Age-Related TDP-43 encephalopathy (LATE) was proposed [9]. LATE explains an amnestic dementia syndrome arising in elderly populations that may occur in isolation or (more commonly) co-morbidly with other neurodegenerative diseases. Neuropathologically, LATE is usually defined and staged by virtue of the presence of intracytoplasmic deposits of TDP-43 within specific, reproducible areas of the neuraxis; early stages originate inclusions within medial limbic structures, while advanced stages show inclusions in cerebral neocortex. Although previous iterations of FGF10 staging schemes for non-ALS/FTLD TDP-43 proteinopathy provided for up to five stages of disease stratification [10,11], the current working group criteria integrate the staging of LATE neuropathologic change (LATE-NC) into stage 1, 2, and 3 TAK-779 disease based upon progressive involvement of amygdala, hippocampus, and midfrontal neocortex, respectively [9]. ALS, FTLD-TDP, and LATE have each been described as capable of producing a neurodegenerative condition independently. However, it is increasingly acknowledged that TDP-43 proteinopathies frequently occur in the context of comorbidity with other neurodegenerative diseases [12], especially LATE [13,14]. As such, sensitive and specific tools for detecting aberrant deposits of TDP-43 protein are needed in order to effectively detect and stage disease, as well as clarify associations between proteinopathies. The neuropathological evaluation of these diseases occurs in human post-mortem material and is most commonly predicated upon study of formalin-fixed, paraffin embedded (FFPE) tissue. Within this tissue medium, immunohistochemistry represents a versatile and widely available testing modality. In this study, we describe the generation and characterization of two novel mouse-derived monoclonal antibodies with elegant specificity for aberrant human TDP-43 inclusions within FFPE tissue of TDP-43 proteinopathies. == Materials and Methods == == Mice == All animal experimental procedures were performed according to University of Florida Institutional Animal Care and Use Committee regulatory guidelines. Mice were housed in a stable environment with a 12-hour light/dark cycle and access to food and water ad libitum. BALB/c mice were procured from the Jackson Laboratory (Bar Harbor, MA). == Commercial TAK-779 Antibodies ==.